When transitioning a patient who is tolerating Wegovy (semaglutide) 2.4 mg weekly without side effects, is it appropriate to start Zepbound (tirzepatide) at the 5 mg weekly dose?

Switching from Wegovy to Zepbound: Starting Dose Recommendation

No, it is not reasonable to start Zepbound at 5 mg when switching from Wegovy 2.4 mg—you should start at the FDA-approved initial dose of 2.5 mg weekly and follow the standard monthly escalation protocol. This approach minimizes gastrointestinal adverse events while maintaining therapeutic benefit, even in patients tolerating the prior GLP-1 RA without issues.

Rationale Based on FDA Labeling and Guidelines

The FDA-approved dosing for tirzepatide (Zepbound) explicitly requires initiation at 2.5 mg weekly with monthly escalation to 5 mg, 10 mg, and ultimately 15 mg 1. This titration schedule was designed based on the SURMOUNT trial data to reduce gastrointestinal adverse events, which occur most commonly during dose escalation 1.

Key point: The 2.5 mg starting dose is not a therapeutic dose—it serves as a tolerability-building phase. The FDA-approved therapeutic doses are 5 mg, 10 mg, and 15 mg weekly 1.

Why Standard Titration Matters Despite Prior GLP-1 RA Tolerance

While your patient tolerates semaglutide 2.4 mg well, tirzepatide has a distinct mechanism as a dual GIP/GLP-1 receptor agonist, not just a selective GLP-1 agonist 1. This dual mechanism produces:

• Different gastrointestinal side effect profile: In SURMOUNT-1, nausea occurred in 10-31% and vomiting in 2-12% of tirzepatide-treated patients, with rates varying by dose 2
• Greater potency: Tirzepatide 15 mg produces ~22.5% weight loss versus semaglutide 2.4 mg's ~15-17% 1
• Novel GIP receptor activation: This adds metabolic effects beyond GLP-1 stimulation alone 1

Evidence from Switching Studies

The most relevant prospective data comes from a 2024 study examining switches from GLP-1 RAs (including semaglutide 0.5-2.0 mg) directly to tirzepatide 5 mg 3. While this study showed acceptable tolerability, it specifically used 5 mg as the starting dose after prior GLP-1 RA exposure—not as an initial dose in treatment-naive patients. Importantly:

• 13.2% developed gastrointestinal events even when starting at 5 mg after prior GLP-1 RA
• 2% discontinued due to adverse events
• The study population had been on stable GLP-1 RA doses for ≥3 months

A 2025 retrospective study suggested that early escalation to 10 mg after starting at 2.5 mg may benefit some patients switching from semaglutide 1.0 mg 4, but this still involved starting at the FDA-approved 2.5 mg dose.

Clinical Algorithm for This Patient

Follow this approach:

1. Week 1-4: Start tirzepatide 2.5 mg weekly

   • Monitor for gastrointestinal symptoms
   • Counsel on expected transient nausea/diarrhea

2. Week 5-8: Escalate to 5 mg weekly

   • This is the first therapeutic dose
   • Assess tolerability and early weight response

3. Week 9-12: Escalate to 10 mg weekly

   • Given prior tolerance of semaglutide 2.4 mg, this patient will likely tolerate escalation well

4. Week 13-16: Escalate to 15 mg weekly (maximum dose)

   • Target dose for optimal weight loss (22.5% reduction) 1

Accelerated option if tolerating perfectly: You could consider escalating every 2-3 weeks instead of 4 weeks if the patient has zero gastrointestinal symptoms, though this is off-label and not supported by FDA guidance 5.

Common Pitfalls to Avoid

• Don't assume cross-tolerance: Semaglutide tolerance doesn't guarantee tirzepatide tolerance due to the added GIP mechanism
• Don't skip the 2.5 mg dose: This increases discontinuation risk from adverse events—2% discontinued even with proper titration 3
• Don't delay escalation unnecessarily: The 2.5 mg dose is sub-therapeutic; move to 5 mg at week 5 as planned
• Monitor hydration: Both medications can cause dehydration, especially if taking insulin or sulfonylureas 2

Practical Considerations

The 2025 AACE Consensus Statement emphasizes that gastrointestinal side effects occur "most commonly during dose escalation" and recommends starting patients "naïve to these medications" at the lowest dose 1. While your patient isn't medication-naïve, they are tirzepatide-naïve, and the dual mechanism warrants the standard approach.

Bottom line: The 4-week titration from 2.5 mg adds only one month to reaching therapeutic dosing but substantially reduces the 13% risk of gastrointestinal adverse events that could lead to discontinuation 3. Given tirzepatide's superior efficacy over semaglutide (20.9% vs 14.9% weight loss) 2, optimizing tolerability to reach the 15 mg maintenance dose should be the priority.